☆ 4.5 Article

Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2022)

Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs

Louis D. Saravolatz et al.

Summary: Molnupiravir and nirmatrelvir-ritonavir are two new oral antiviral drugs for outpatient treatment of mild to moderate COVID-19. Both drugs have shown a reduction in death and hospitalization when started within 5 days of symptom onset.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Immunology

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients

Ronza Najjar-Debbiny et al.

Summary: This study assessed the effectiveness of Paxlovid in high-risk COVID-19 patients in real-world settings. The findings demonstrate that Paxlovid is highly effective in reducing the risk of death and severe COVID-19 in the Omicron era. The study also suggests that Paxlovid may be more effective in older patients, immunosuppressed patients, and patients with underlying neurological or cardiovascular disease. Vaccination status did not significantly impact the effectiveness of Paxlovid.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Medicine, General & Internal

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Jennifer Hammond et al.

Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Editorial Material Urology & Nephrology

Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD

Swapnil Hiremath et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

添加到收藏夹

Article Chemistry, Analytical

Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum

Katharina Habler et al.

Summary: A method for accurate quantification of several COVID-19 treatment drugs in serum was developed and validated in this study. The method was validated based on the European Medicines Agency bioanalytical method validation protocol and showed robust validation results.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2021)

添加到收藏夹

Article Biochemical Research Methods

Determination of lopinavir and ritonavir in blood plasma, seminal plasma, saliva and plasma ultra-filtrate by liquid chromatography/tandem mass spectrometry detection

Rita C. E. Estrela et al.

RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2008)

添加到收藏夹

Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19

相关参考文献

Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD

Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum

Determination of lopinavir and ritonavir in blood plasma, seminal plasma, saliva and plasma ultra-filtrate by liquid chromatography/tandem mass spectrometry detection

导出引文

分享论文